The patient's vital signs don't look good. The outlook for the future is worsening. And there are signs that the patient needs to be examined for other possible problems. Should someone call an ambulance for large hospital chain HMA (NYSE: HMA ) ?
Weak vitals and outlook
If admissions serve as the pulse for a hospital, HMA's heart beat is slowing. Admissions dropped 8.8% during the first quarter, with adjusted admissions falling 5.8%. HMA says that fewer uninsured admissions and big increases in observation stays caused the declines.
Surgeries were also down by 5.6%. I'm not sure what vital sign we can use as a comparison, but a lower number isn't good news for a hospital operator.
As a result of these falling metrics, HMA reported first-quarter earnings of $0.13 per diluted share, much lower than the $0.24 per diluted share from the same period last year. The company also missed the average analysts' estimate of $0.15 per share.
HMA announced first quarter revenue of $1.48 billion, virtually unchanged from the first quarter of 2012. Analysts expected $1.66 billion -- another miss. All of this negative news led HMA to lower its outlook for the full year a couple of weeks ago to $0.86 to $0.95 per share.
Further examination required
As if all this isn't bad enough, HMA also revealed that it received a subpoena from the Securities and Exchange Commission on April 25. The SEC asked for financial documents for Medicare, Medicaid, privately insured, and uninsured patient accounts. HMA said that its management is cooperating fully with the investigation.
At this point, there's no way to know what will come of this SEC probe. HMA hit the nail on the head when they said the company was "unable to determine the potential impact, if any, of this investigation." It could ultimately amount to nothing. On the other hand, the investigation could present serious problems.
The combination of the SEC subpoena news and the first-quarter results caused HMA shares to fall more than 6% in early trading on Friday. The patient is clearly in pain.
Call an ambulance?
HMA's woes appear to be worse than its fellow hospital operators. HCA Holdings (NYSE: HCA ) , the nation's largest hospital chain, also reported sluggish admissions and weakening outpatient volumes in the first quarter. This dragged down HCA shares during much of April, but the stock has since rebounded.
Community Health Systems (NYSE: CYH ) and Tenet Healthcare (NYSE: THC ) stocks also struggled during most of April. However, the weakness in the two companies' shares probably stemmed more from analyst downgrades over valuation concerns. Like HCA, Community Health and Tenet have both seen shares come back strongly in the past week or so.
Part of the problem for HMA stems from an unflattering 60 Minutes segment aired last December. Some speculate that the TV news program's story on the company contributed to fewer admissions.
Despite HMA's multitude of problems, I don't think anyone needs to call an ambulance just yet. The company, like its peers, should benefit from Obamacare in the days ahead if more uninsured Americans gain insurance as promised.
However, I wouldn't recommend buying HMA shares right now. It's probably wise to hold off until more is known about the SEC investigation. If HMA receives more bad news on that front, though, turn on the sirens.
Does the U.S. need medical attention for a tapeworm infestation? Warren Buffett referred to a macro trend by saying "this is the tapeworm that's eating at American competitiveness." What is this tapeworm? Find out in our free report: "What's Really Eating At America's Competitiveness." You'll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.